As mentioned earlier, PARP inhibition was first described in cancer cells with defective BRCA1/BRCA2 protein function, and then clinical trials confirmed the effectiveness of PARP inhibitors as monotherapy in patients with BRCA1(−/−) and BRCA2(−/−) tumors [196]. This evidence concerns the gene BRCA2 and cancer.